Midlands and Lancashire Commissioning Support Unit, Old Market House, Birkenhead, Wirral, CH41 5AL, UK.
School of Pharmacy and Life Sciences, Robert Gordon University, Riverside East, Garthdee Road, Aberdeen, AB10 1JG, UK.
Int J Clin Pharm. 2017 Feb;39(1):173-180. doi: 10.1007/s11096-016-0419-x. Epub 2017 Jan 3.
Background Updated evidence-based guidelines for the management of atrial fibrillation (AF) necessitate patient review, particularly with respect to oral anticoagulants, to ensure maximum health gain around stroke prophylaxis. Objective To quantify the level of anticoagulation utilisation in patients with a CHADS-VASc ≥1/≥2 (male/female) according to evidence-based guidelines and to assess the impact of a pharmacist-led intervention to optimise therapy. Setting Fifteen general medical practices in Liverpool, North-West England with a practice population of 99,129. Method GRASP-AF software was employed to interrogate patient electronic medical records to identify and risk stratify AF patients (using CHADS-VASc). A pharmacist then reviewed the medical records of those of patients not anticoagulated and with a CHADS-VASc ≥1/≥2 (male/female). Recommendations were discussed with a general practitioner (GP) and those patients in whom the need for anticoagulation was agreed were invited for a consultation with either the pharmacist or GP and therapy optimised where appropriate. The GPs were responsible for managing those patients referred for diagnosis confirmation or further specialist opinion. Main outcome measure Proportion of patients eligible/not eligible for anticoagulation; proportions in whom anticoagulants initiated, refused, antiplatelets discontinued. Results Five hundred and twenty-three patients (31% of patients identified with AF and a CHADS-VASc ≥1/≥2 (male/female)) were not receiving an anticoagulant (26 subsequently died or left the practice leaving 497). Three hundred and eighty-two (77%) pharmacist recommendations to a GP were agreed without modification. Following outcomes of diagnostic investigations and specialist referrals, 202 (41%) patients were candidates for anticoagulation, 251 (51%) were not eligible for anticoagulation, 103 (21%) were anticoagulated (56 warfarin, 47 DOAC). Conclusion A pharmacist-led intervention re-aligned oral anticoagulant therapy to the latest evidence based guidelines for stroke prophylaxis, whilst simultaneously correcting the over-utilisation of antiplatelet therapy.
背景 房颤(AF)管理的最新循证指南需要对患者进行复查,尤其是在口服抗凝剂方面,以确保在预防中风方面获得最大的健康收益。 目的 根据循证指南,量化 CHADS-VASc≥1/≥2(男性/女性)的房颤患者的抗凝使用率,并评估药师主导的干预措施优化治疗的效果。 地点 英格兰西北部利物浦的 15 家普通医疗实践,其患者群体为 99129 人。 方法 使用 GRASP-AF 软件查询患者电子病历,以识别和风险分层房颤患者(使用 CHADS-VASc)。然后,药剂师审查未接受抗凝治疗且 CHADS-VASc≥1/≥2(男性/女性)的患者的病历。与全科医生(GP)讨论建议,对于那些需要抗凝的患者,邀请药剂师或 GP 进行咨询,并在适当的情况下优化治疗。GP 负责管理那些被转介进行诊断确认或进一步专科意见的患者。 主要结果 适合/不适合抗凝的患者比例;开始抗凝、拒绝抗凝、停用抗血小板药物的比例。 结果 523 名患者(31%的患者被诊断为 AF 且 CHADS-VASc≥1/≥2(男性/女性))未接受抗凝治疗(26 人随后死亡或离开诊所,留下 497 人)。药剂师向 GP 提出的 382 项建议未经修改即获得同意。经过诊断性检查和专科转介的结果,202 名(41%)患者适合抗凝,251 名(51%)不适合抗凝,103 名(21%)接受抗凝治疗(56 名华法林,47 名 DOAC)。 结论 药师主导的干预措施使口服抗凝治疗与预防中风的最新循证指南相一致,同时纠正了抗血小板治疗的过度使用。